Form 4: Moleculin Biotech CFO Jonathan P. Foster Reports Changes in Beneficial Ownership

Sentiment:

SEC Form 4 Filing


Jonathan P. Foster, CFO of Moleculin Biotech, reports the vesting and subsequent sale of shares to cover tax obligations.

Summary

  • On June 20, 2024, Jonathan P. Foster, the Chief Financial Officer of Moleculin Biotech, Inc., reported changes in his beneficial ownership of the company's stock.
  • Foster acquired 2,712 shares of common stock through the vesting of restricted stock units.
  • Simultaneously, he disposed of 636 shares to cover tax obligations related to the vesting at a price of $3.78 per share.
  • Following these transactions, Foster directly owns 8,087 shares of Moleculin Biotech common stock and 69,166 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation and tax obligations.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be an indicator of management's confidence in the company's prospects.

Key Dates

DateDescription
06/20/2022Reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
06/20/2024Date of transaction: acquisition of 2,712 shares via restricted stock units and disposal of 636 shares for tax obligations.
06/21/2024Date of signature for the report.

Keywords

Moleculin Biotech, MBRX, Form 4, Beneficial Ownership, Jonathan P. Foster, CFO, Restricted Stock Units, Vesting, Tax Obligations

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.